Ignyta Inc. (RXDX) 9.42 $RXDX
Ignyta Announces Multiple Presentations at the 2015 AACR Annual Meeting
Business Wire - Sat Apr 18, 12:00PM CDT
Ignyta, Inc. (Nasdaq:RXDX), a precision oncology biotechnology company, today announced three poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2015 in Philadelphia, Pennsylvania.
RXDX: 9.42 (-0.16)
InsiderInsights.com Daily Round Up 3/24/15: FANG, GLP, CPTA, ANET
InsiderInsights - at Seeking Alpha - Wed Mar 25, 12:50PM CDT
EGLE: 8.50 (-0.19), ANET: 66.39 (+0.24), MMI: 37.42 (-0.40), BUI: 19.85 (+0.04), LLY: 71.58 (-0.82), HRZN: 14.30 (+0.06), K: 63.73 (-0.12), WIW: 11.55 (+0.04), CPTA: 17.67 (+0.02), GLP: 41.41 (+0.90), WD: 19.52 (+0.76), RXDX: 9.42 (-0.16), CVEO: 3.43 (-0.06), DYN: 33.53 (+0.86), FANG: 79.83 (-2.13), ZAYO: 27.20 (-0.05), BDJ: 8.24 (-0.05), ROST: 104.38 (-0.13), ALCO: 47.11 (-0.65), WIA: 11.69 (+0.03)
InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT
MPW: 14.67 (+0.07), SSNC: 63.62 (-1.08), SANW: 4.51 (+0.01), ADMA: 9.00 (unch), ASPS: 23.24 (+0.76), MMI: 37.42 (-0.40), PSA: 193.60 (+0.56), ENOC: 11.39 (+0.12), PCLN: 1,233.09 (+11.99), CGIX: 10.07 (-0.05), FDS: 159.73 (+0.05), GGP: 28.78 (+0.05), NEE: 105.05 (+0.77), DO: 29.82 (-0.58), RXDX: 9.42 (-0.16), DYN: 33.53 (+0.86), TCB: 15.47 (+0.06), TWTR: 50.82 (-0.59), RGS: 17.26 (-0.11)
Investors Relieved? Akorn Stock Retakes 50-Day Line
at Investor's Business Daily - Wed Mar 18, 2:45PM CDT
Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by...
ESPR: 104.60 (-4.29), RXDX: 9.42 (-0.16), AKRX: 55.24 (-0.68), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), NKTR: 10.77 (-0.29), REGN: 480.09 (+0.01)
Teva Sells Four Oncology Development Assets to Ignyta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 2:44PM CDT
Teva (TEVA) announced the sale of its worldwide rights and assets related to four targeted oncology development programs to Ignyta Inc. (RXDX), for 1.5 million shares of Ignyta???s stock.
RXDX: 9.42 (-0.16), AKRX: 55.24 (-0.68), TEVA: 64.41 (+1.16), ACOR: 33.12 (-0.38)
Ignyta incurs higher net loss of USD40.0m in 2014
M2 - Wed Mar 18, 6:04AM CDT
Oncology company Ignyta (Nasdaq:RXDX) disclosed on Tuesday that it recorded a net loss of USD40.0m (USD2.18 per share) for the full year ended 31 December 2014.
RXDX: 9.42 (-0.16)
Ignyta's (RXDX) CEO Jonathan Lim on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 7:50PM CDT
RXDX: 9.42 (-0.16)
Akorn Leads 5 Drug Stocks Moving After Hours On News
at Investor's Business Daily - Tue Mar 17, 7:10PM CDT
IBD's top two industries this week are Medical-Biotech/Biomed and Medical-Generic Drugs. Several companies from these top groups reported market-moving news after Tuesday's market close. Here are five: Akorn Restates, Stock Rises Akorn (AKRX) late...
ACT: 295.41 (-2.95), ESPR: 104.60 (-4.29), RXDX: 9.42 (-0.16), AKRX: 55.24 (-0.68), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), NKTR: 10.77 (-0.29), REGN: 480.09 (+0.01)
Ignyta up 31% after hours on Teva oncology deal
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:37PM CDT
RXDX: 9.42 (-0.16), TEVA: 64.41 (+1.16)
Ignyta reports FY'14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:22PM CDT
RXDX: 9.42 (-0.16)
Ignyta Announces 2014 Full Year Company Highlights and Financial Results
Business Wire - Tue Mar 17, 3:15PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the full year ended December 31, 2014.
RXDX: 9.42 (-0.16)
Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva
Business Wire - Tue Mar 17, 3:00PM CDT
--Concurrent $42 million equity investment in Ignyta by Teva and selected healthcare investors
RXDX: 9.42 (-0.16), TEVA: 64.41 (+1.16)
Ignyta to Report 2014 Company Highlights and Financial Results and Host Conference Call and Webcast on March 17, 2015
Business Wire - Wed Mar 11, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it will release its 2014 financial results after the market closes on Tuesday, March 17, 2015. Ignyta management will host a conference call that same afternoon at 5:00 p.m. ET (2:00 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 9.42 (-0.16)
Ignyta inks equity offering with Cantor Fitzgerald
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 7:07AM CST
RXDX: 9.42 (-0.16)
Ignyta's Lead Drug Gets Orphan Status for Colorectal Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 12:30PM CST
Ignyta, Inc. (RXDX) announced that the FDA has granted orphan drug designation to its lead candidate entrectinib for the treatment of ALK-positive colorectal cancer
LCI: 67.40 (unch), RXDX: 9.42 (-0.16), SLXP: 172.96 (+0.15), SCMP: 21.09 (-0.31)
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST
LOXO: 13.60 (+0.21), TSRO: 64.00 (-0.65), RXDX: 9.42 (-0.16), PFE: 35.27 (-0.09), MRTX: 27.87 (-0.15), NVS: 104.28 (-1.22), ARRY: 7.19 (-0.12)
Ignyta's lead product an Orphan Drug for colorectal cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 6:22AM CST
RXDX: 9.42 (-0.16)
Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer
Business Wire - Tue Feb 17, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta's lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.
RXDX: 9.42 (-0.16)
Ignyta's entrectinib an Orphan Drug for subset of NSCLC
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 7:46AM CST
RXDX: 9.42 (-0.16)
Ignyta Announces Multiple Presentations at the 2015 AACR Annual Meeting
Business Wire - Sat Apr 18, 12:00PM CDT
Ignyta, Inc. (Nasdaq:RXDX), a precision oncology biotechnology company, today announced three poster presentations at the 106th Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2015 in Philadelphia, Pennsylvania.
RXDX: 9.42 (-0.16)
InsiderInsights.com Daily Round Up 3/24/15: FANG, GLP, CPTA, ANET
InsiderInsights - at Seeking Alpha - Wed Mar 25, 12:50PM CDT
EGLE: 8.50 (-0.19), ANET: 66.39 (+0.24), MMI: 37.42 (-0.40), BUI: 19.85 (+0.04), LLY: 71.58 (-0.82), HRZN: 14.30 (+0.06), K: 63.73 (-0.12), WIW: 11.55 (+0.04), CPTA: 17.67 (+0.02), GLP: 41.41 (+0.90), WD: 19.52 (+0.76), RXDX: 9.42 (-0.16), CVEO: 3.43 (-0.06), DYN: 33.53 (+0.86), FANG: 79.83 (-2.13), ZAYO: 27.20 (-0.05), BDJ: 8.24 (-0.05), ROST: 104.38 (-0.13), ALCO: 47.11 (-0.65), WIA: 11.69 (+0.03)
InsiderInsights.com Daily Round Up 3/18/15: DO, ASPS, CGIX, ADMA
InsiderInsights - at Seeking Alpha - Thu Mar 19, 11:55AM CDT
MPW: 14.67 (+0.07), SSNC: 63.62 (-1.08), SANW: 4.51 (+0.01), ADMA: 9.00 (unch), ASPS: 23.24 (+0.76), MMI: 37.42 (-0.40), PSA: 193.60 (+0.56), ENOC: 11.39 (+0.12), PCLN: 1,233.09 (+11.99), CGIX: 10.07 (-0.05), FDS: 159.73 (+0.05), GGP: 28.78 (+0.05), NEE: 105.05 (+0.77), DO: 29.82 (-0.58), RXDX: 9.42 (-0.16), DYN: 33.53 (+0.86), TCB: 15.47 (+0.06), TWTR: 50.82 (-0.59), RGS: 17.26 (-0.11)
Investors Relieved? Akorn Stock Retakes 50-Day Line
at Investor's Business Daily - Wed Mar 18, 2:45PM CDT
Akorn (AKRX) shares made big gains in the stock market today. The drugmaker had to restate its Q2 and Q3 2014 financial statements because of an error that led to an overstatement of revenue and earnings in Q2. But investors seem to be relieved by...
ESPR: 104.60 (-4.29), RXDX: 9.42 (-0.16), AKRX: 55.24 (-0.68), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), NKTR: 10.77 (-0.29), REGN: 480.09 (+0.01)
Teva Sells Four Oncology Development Assets to Ignyta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 18, 2:44PM CDT
Teva (TEVA) announced the sale of its worldwide rights and assets related to four targeted oncology development programs to Ignyta Inc. (RXDX), for 1.5 million shares of Ignyta???s stock.
RXDX: 9.42 (-0.16), AKRX: 55.24 (-0.68), TEVA: 64.41 (+1.16), ACOR: 33.12 (-0.38)
Ignyta incurs higher net loss of USD40.0m in 2014
M2 - Wed Mar 18, 6:04AM CDT
Oncology company Ignyta (Nasdaq:RXDX) disclosed on Tuesday that it recorded a net loss of USD40.0m (USD2.18 per share) for the full year ended 31 December 2014.
RXDX: 9.42 (-0.16)
Ignyta's (RXDX) CEO Jonathan Lim on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 17, 7:50PM CDT
RXDX: 9.42 (-0.16)
Akorn Leads 5 Drug Stocks Moving After Hours On News
at Investor's Business Daily - Tue Mar 17, 7:10PM CDT
IBD's top two industries this week are Medical-Biotech/Biomed and Medical-Generic Drugs. Several companies from these top groups reported market-moving news after Tuesday's market close. Here are five: Akorn Restates, Stock Rises Akorn (AKRX) late...
ACT: 295.41 (-2.95), ESPR: 104.60 (-4.29), RXDX: 9.42 (-0.16), AKRX: 55.24 (-0.68), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), NKTR: 10.77 (-0.29), REGN: 480.09 (+0.01)
Ignyta up 31% after hours on Teva oncology deal
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:37PM CDT
RXDX: 9.42 (-0.16), TEVA: 64.41 (+1.16)
Ignyta reports FY'14 results
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:22PM CDT
RXDX: 9.42 (-0.16)
Ignyta Announces 2014 Full Year Company Highlights and Financial Results
Business Wire - Tue Mar 17, 3:15PM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the full year ended December 31, 2014.
RXDX: 9.42 (-0.16)
Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva
Business Wire - Tue Mar 17, 3:00PM CDT
--Concurrent $42 million equity investment in Ignyta by Teva and selected healthcare investors
RXDX: 9.42 (-0.16), TEVA: 64.41 (+1.16)
Ignyta to Report 2014 Company Highlights and Financial Results and Host Conference Call and Webcast on March 17, 2015
Business Wire - Wed Mar 11, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it will release its 2014 financial results after the market closes on Tuesday, March 17, 2015. Ignyta management will host a conference call that same afternoon at 5:00 p.m. ET (2:00 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 9.42 (-0.16)
Ignyta inks equity offering with Cantor Fitzgerald
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 7:07AM CST
RXDX: 9.42 (-0.16)
Ignyta's Lead Drug Gets Orphan Status for Colorectal Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 12:30PM CST
Ignyta, Inc. (RXDX) announced that the FDA has granted orphan drug designation to its lead candidate entrectinib for the treatment of ALK-positive colorectal cancer
LCI: 67.40 (unch), RXDX: 9.42 (-0.16), SLXP: 172.96 (+0.15), SCMP: 21.09 (-0.31)
Investing In Precision Oncology: Targeting NTRK Genomic Alterations
Bay Area Biotech - at Seeking Alpha - Wed Feb 18, 10:44AM CST
LOXO: 13.60 (+0.21), TSRO: 64.00 (-0.65), RXDX: 9.42 (-0.16), PFE: 35.27 (-0.09), MRTX: 27.87 (-0.15), NVS: 104.28 (-1.22), ARRY: 7.19 (-0.12)
Ignyta's lead product an Orphan Drug for colorectal cancer
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 6:22AM CST
RXDX: 9.42 (-0.16)
Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer
Business Wire - Tue Feb 17, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Ignyta's lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.
RXDX: 9.42 (-0.16)
Ignyta's entrectinib an Orphan Drug for subset of NSCLC
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 7:46AM CST
RXDX: 9.42 (-0.16)
